Drug intelligence / Profile preview

WT-X28

Development stage: Preclinical
Lead developer: Hangzhou Westan Pharmaceutical Technology
Modality: Small Molecules

Overview

WT-X28 is a small molecule drug candidate being developed by Hangzhou Westan Pharmaceutical Technology for the treatment of respiratory diseases. It is currently in the preclinical phase of development, specifically in the target selection and validation stage. Hangzhou Westan Pharmaceutical Technology is a biotech company focused on the discovery and development of innovative therapies for respiratory and inflammatory diseases, leveraging expertise in medicinal chemistry and drug delivery. As of now, the specific molecular target and pharmacological profile of WT-X28 have not been disclosed to the public.

Beyond the preview

Go deeper on WT-X28.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WT-X28.

Explore the full profile